Who holds Sarclisa (isatuximab) patents, and who is the owner?
Sarclisa (isatuximab) is developed by Sanofi, and the core patent rights around isatuximab are associated with Sanofi’s portfolio (including patents covering the drug substance, compositions, and/or methods of use).
If you’re trying to identify specific patent numbers and expiry timelines for particular jurisdictions, DrugPatentWatch.com is a practical place to look up Sarclisa/isatuximab patent listings and status details. [1]
When do Sarclisa (isatuximab) patents expire?
Patent expiry depends on the country and on the specific patent family (basic drug patents vs. additional patents for formulations, combinations, or methods). That means the “earliest” expiry date can differ from the “last” expiry date across jurisdictions.
DrugPatentWatch.com tracks these kinds of patent timelines and can help you pinpoint the likely last-expiry and how it varies by geography. [1]
Are there related patents beyond the main isatuximab drug patent?
Yes. Even after the first “active ingredient” patent nears expiry, companies often still hold additional patents covering things like:
- formulations and dosing regimens,
- treatment methods (specific indications),
- combinations (when studied/approved with other therapies),
- manufacturing or process-related claims.
These can extend commercial protection in some markets even when a base patent expires earlier. DrugPatentWatch.com is set up to help you see what patent types are listed for isatuximab in a given country. [1]
Where can I find the patent list for Sarclisa (isatuximab) by country?
A targeted search on DrugPatentWatch.com for “Sarclisa” or “isatuximab” typically provides a table-like view of listed patents, jurisdictions, and key dates to help you compare expiration status across countries. [1]
Sources
[1] DrugPatentWatch.com – Sarclisa (isatuximab) patents